A recent study took a similar approach; bempedoic acid in combination with cell cycle kinase inhibitors (palbociclib targeting CDK4/6) reduced cell viability and invasion in a panel of breast and pancreatic cancer cell lines [93]. This evidence concerns the gene CDK4 and familial pancreatic carcinoma.